Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 known ✓ | P25021 | 1/20 | 0.30 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.30 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 2/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL522782 | 1.00 | MAPK1 (0.40) | MAPK1NOS1NOS3NOS2LTA4H | |
| Hydrochloric Acid SCHEMBL522784 | 1.00 | MAPK1 (0.40) | MAPK1NOS1NOS3NOS2LTA4H | |
| SCHEMBL522812 | 0.98 | MAPK1 (0.41) | MAPK1NOS1NOS3NOS2LTA4H | |
| SCHEMBL522783 | 0.98 | MAPK1 (0.41) | MAPK1NOS1NOS3NOS2LTA4H | |
| SCHEMBL3080102 | 0.98 | MAPK1 (0.41) | MAPK1NOS1NOS3NOS2LTA4H | |
| SCHEMBL12936767 | 0.86 | NOS1 (0.36) | NOS1NOS3NOS2LTA4HSLC7A5 | |
| Hydrochloric Acid SCHEMBL6435071 | 0.86 | NOS1 (0.36) | NOS1NOS3NOS2LTA4HSLC7A5 | |
| SCHEMBL30227945 | 0.86 | NOS1 (0.36) | NOS1NOS3NOS2LTA4HSLC7A5 | |
| SCHEMBL2735019 | 0.86 | NOS1 (0.36) | NOS1NOS3NOS2LTA4HSLC7A5 | |
| Hydrochloric Acid SCHEMBL1304617 | 0.84 | MAPK1 (0.40) | MAPK1HRH2HRH1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119241385-A | Beta-acyloxy enamide derivative and preparation method and application thereof | 江西师范大学 | 2025-01-03 | — | — | CN | claimed |
| US-20230117289-A1 | COMPOSITIONS COMPRISING METHYLPHENIDATE-PRODRUGS, PROCESSES OF MAKING AND USING THE SAME | COMMAVE THERAPEUTICS SA (CH) | 2023-04-20 | — | — | US | claimed |
| CN-115666534-A | Compositions comprising methylphenidate prodrugs, methods of making and using the same | 肯法姆股份有限公司 | 2023-01-31 | — | — | CN | claimed |
| EP-4110304-A1 | COMPOSITIONS COMPRISING METHYLPHENIDATE-PRODRUGS, PROCESSES OF MAKING AND USING THE SAME | KemPharm, Inc. (US) | 2023-01-04 | — | — | EP | claimed |
| CN-119241385-B | Beta-acyloxy enamide derivative and preparation method and application thereof | 江西师范大学 | 2025-03-25 | — | — | CN | disclosed |
| CN-119241385-A | Beta-acyloxy enamide derivative and preparation method and application thereof | 江西师范大学 | 2025-01-03 | — | — | CN | disclosed |
| US-20230117289-A1 | COMPOSITIONS COMPRISING METHYLPHENIDATE-PRODRUGS, PROCESSES OF MAKING AND USING THE SAME | COMMAVE THERAPEUTICS SA (CH) | 2023-04-20 | — | — | US | disclosed |
| CN-115666534-A | Compositions comprising methylphenidate prodrugs, methods of making and using the same | 肯法姆股份有限公司 | 2023-01-31 | — | — | CN | disclosed |
| EP-4110304-A1 | COMPOSITIONS COMPRISING METHYLPHENIDATE-PRODRUGS, PROCESSES OF MAKING AND USING THE SAME | KemPharm, Inc. (US) | 2023-01-04 | — | — | EP | disclosed |
| US-11512108-B2 | Method for producing amide compound | CHUBU UNIVERSITY EDUCATIONAL FOUNDATION (JP) | 2022-11-29 | — | — | US | disclosed |
| CN-108863963-B | Heterocyclic compounds as PD-L1 inhibitors | 南京圣和药物研发有限公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-112062704-B | Preparation method of trifluoromethylated polypeptide compound | 浙江工业大学 | 2022-03-18 | — | — | CN | disclosed |
| WO-2002064550-A1 | GLUCOCORTICOID RECEPTOR MODULATORS | ABBOTT LABORATORIES (US) | 2002-08-22 | — | — | WO | disclosed |
| WO-2002050051-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2002-06-27 | — | — | WO | disclosed |
| EP-1072591-A1 | NOVEL UREA DERIVATIVES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-01-31 | — | — | EP | disclosed |
| US-6093731-A | Isoquinolines | PFIZER INC. | 2000-07-25 | — | — | US | disclosed |
| US-5840918-A | PEPTIDOMIMETIC COMPOUNDS USEFUL IN THE TREATMENT OF RAS-ASSOCIATED HUMAN CANCERS | EISAI CO., LTD. (JP) | 1998-11-24 | — | — | US | disclosed |
| EP-0750609-A4 | ISOPRENYL TRANSFERASE INHIBITORS | EISAI CO LTD (JP) | 1997-09-24 | — | — | EP | disclosed |
| EP-0750609-A1 | ISOPRENYL TRANSFERASE INHIBITORS | Eisai Co., Ltd. (JP) | 1997-01-02 | — | — | EP | disclosed |
| WO-1995025086-A1 | ISOPRENYL TRANSFERASE INHIBITORS | EISAI CO., LTD. (JP) | 1995-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230117289-A1 | COMPOSITIONS COMPRISING METHYLPHENIDATE-PRODRUGS, PROCESSES OF MAKING AND USING THE SAME | COMT, CYP3A4, CYP2C19 | HRH2 3814/4885HRH1 3801/4885CA2 4016/4885 |
| US-11512108-B2 | Method for producing amide compound | BCAT2, ASNS, VIP | HRH2 1218/4885HRH1 2193/4885CA2 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.